Blood and Marrow Transplant Clinical Trials Network

血液和骨髓移植临床试验网络

• 批准号: 7125309
• 负责人: KIRK R Schultz
• 金额: $ 20.29万
• 依托单位: NATIONAL CHILDHOOD CANCER FOUNDATION
• 依托单位国家: 美国
• 财政年份: 2001
• 资助国家: 美国
• 起止时间: 2001-09-30 至 2011-07-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7125309
• 关键词: bone marrow transplantation; clinical research; clinical trials; cooperative study; disease /disorder prevention /control; hematopoietic tissue transplantation; human subject; human therapy evaluation; infection; patient oriented research; pediatrics; stem cell transplantation

DESCRIPTION (provided by applicant): Hematopoietic stem cell (HCT) transplantation offers curative therapy for a variety of malignant and nonmalignant disorders. It is limited by donor availability, transplant related toxicity, graft vs. host disease (GVHD), malignant relapse, infections, and for some patients, reduction in their post-transplant quality of life. Continuing progress from the previous funding period, the Blood and Marrow Transplant Clinical Trials Network (BMT CTN) proposes to develop and execute scientifically meritorious, prospective clinical trials addressing key issues in HCT. We will conduct multicenter Phase II and more importantly, prospective Phase III trials in six key areas including: alternative donors and graft sources; regimen related toxicity; GVHD; disease recurrence; infection and immune reconstitution; and late effects and quality of life. Due to the complexity of pediatric transplantation, especially in those with rare inherited disorders, which are complex and difficult to study, we will devote special attention and focused scientific expertise to using the coordinated strength of the Network to improve BMT outcomes for this unique population. The BMT CTN will also amplify and leverage Network resources through collaborative research and ancillary studies of biologic endpoints that will be integrated with and complement clinical endpoints. The Network will also seek active collaboration with other scientific bodies including NCI- funded Cancer Cooperative Groups to improve the efficiency of clinical transplant studies for the large number of patients who could benefit from BMT and to maximize our successful completion of high quality and high priority clinical trials. (End of abstract.)

描述（由申请人提供）： 造血干细胞（HCT）移植为各种恶性和非恶性疾病提供治疗疗法。它受到供体的可用性，相关毒性，移植物与宿主疾病（GVHD），恶性复发，感染和某些患者的限制，减少了移植物后植物的生活质量。从上一个资金期间，血液和骨髓移植临床试验网络（BMT CTN）的持续进展提议开发和执行科学上有色的，前瞻性的临床试验，以解决HCT中的关键问题。我们将在六个关键领域进行多中心II期，更重要的是前瞻性III期试验，包括：替代捐助者和移植物来源；方案相关的毒性； GVHD;疾病复发；感染和免疫机构；以及后期的影响和生活质量。由于小儿移植的复杂性，尤其是在罕见的遗传疾病（复杂且难以研究的疾病的患者中），我们将专注于特殊的关注，并以科学专业知识来利用网络的协调力量来改善这个独特人群的BMT成果。 BMT CTN 还将通过对生物终点的合作研究和辅助研究来扩大和利用网络资源，并将其与临床终点集成并补充临床终点。该网络还将寻求与其他科学机构的积极合作，包括NCI融资癌症合作群体，以提高可从BMT中受益的大量患者的临床移植研究效率，并最大程度地完成我们成功完成高质量和高优先级临床试验的效率。 （摘要结束。）